At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Ruxolitinib 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib and Erlotinib for Lung Cancer. Completed, enrolled 22 participants across 6 sites.
Detailed Summary
This is a phase 2 study. The goal of this study is to find out what effects, good and/or bad, taking erlotinib and ruxolitinib has on the patients and on lung cancer. Erlotinib and ruxolitinib are FDA approved for other indications, but the use of erlotinib and ruxolitinib together has not been studied before and is not FDA-approved.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionOct 2017
TodayJul 2026
First PostedJun 4, 2014
Enrollment StartJun 1, 2014
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.1 years ago
Interventions
Ruxolitinibdrug
Ruxolitinib 10mg PO BID Ruxolitinib 15mg PO BID Ruxolitinib 20mg PO BID
Erlotinibdrug
Erlotinib 150mg PO QD